P/E - Prostatype Genomics AB (F:PGO) - Alpha Spread
P

Prostatype Genomics AB
F:PGO

Watchlist Manager
Prostatype Genomics AB
F:PGO
Watchlist
Price: 0.0012 EUR Market Closed
Market Cap: 1.2m EUR
Have any thoughts about
Prostatype Genomics AB?
Write Note

P/E
Price to Earnings

-0.5
Current
-9.8
Median
23.9
Industry
Higher than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-0.5
=
Market Cap
18.8m SEK
/
Net Income
-40.5m SEK
All Countries
Close
Earnings Growth
SE
P
Prostatype Genomics AB
F:PGO
Average P/E: 57.6
Negative Multiple: -0.5
N/A
US
Abbvie Inc
NYSE:ABBV
64.5
406%
US
Amgen Inc
NASDAQ:AMGN
57.7
74%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29.8
56%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -252.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
99.7
71%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -504 N/A
AU
CSL Ltd
ASX:CSL
36.4
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.3 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 169.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -483 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-0.2
2-Years Forward
P/E
N/A
3-Years Forward
P/E
N/A

See Also

Discover More